The FDA apparently deems an uncontrolled study acceptable – five months after saying no.
ApexOnco Front Page
Recent articles
Could RO7851624, newly into clinical trials, be RG6735?
The company reveals the first overall survival data in adjuvant ER-positive breast cancer.
Imfinzi and sasanlimab look nearly identical, but it’s a different story for Roche’s Tecentriq.
The company has seen a PFS and OS benefit in the phase 3 Majestec-3 trial.
A second phase 3 trial is slated for Astra’s CD19 T-cell engager surovatamig.
First data with Astra’s torvutatug samrotecan come as Lilly unveils its first folate pivotal trial.
But more detail is awaited, especially on toxicity.